1. Indications:

Osikin (Osimertinib) 80 mg is indicated for the treatment of:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) T790M mutation, detected by an FDA-approved test, as the first-line treatment.
• Metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations, detected by an FDA-approved test, after progression on EGFR tyrosine kinase inhibitor (TKI) therapy.

2. Pharmacology:

Osikin (Osimertinib) 80 mg exerts its pharmacological effects by selectively inhibiting the activity of mutant forms of the epidermal growth factor receptor (EGFR), particularly those with the T790M mutation. By targeting these specific mutations, Osikin inhibits EGFR signaling pathways involved in cancer cell proliferation and survival, ultimately leading to tumor regression and inhibition of cancer progression.

3. Dosage and Administration:

The recommended dosage of Osikin (Osimertinib) 80 mg may vary depending on the type of lung cancer being treated and individual patient characteristics. Typically, the prescribed dose is 80 mg taken orally once daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Osikin (Osimertinib) 80 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Osikin.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Osikin, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Osikin (Osimertinib) 80 mg may include:

• Diarrhea
• Rash
• Nausea
• Fatigue
• Decreased appetite
• Dry skin

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Osikin (Osimertinib) 80 mg, patients should be aware of the following precautions:

• Osikin may cause interstitial lung disease (ILD) or pneumonitis, which can be fatal. Patients should be monitored closely for respiratory symptoms and undergo regular imaging studies during treatment.
• Cardiomyopathy, including left ventricular dysfunction, has been reported with Osikin. Cardiac function should be monitored periodically during treatment.
• Osikin may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least six weeks after the last dose.

7. Overdose Effects:

In case of overdose with Osikin (Osimertinib) 80 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Osikin overdose, and patients should seek immediate medical attention if overdose is suspected.